Filing Flows › ADC Therapeutics SA (ADCT) › Next earnings date
ADC Therapeutics SA (ADCT) earnings on Nov 9, 2026: what to expect
ADC Therapeutics SA (ADCT) is expected to report earnings on Nov 9, 2026, tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.21 (−$0.27 to −$0.19, 5 estimates) on revenue of $19.1M, against −$0.30 and $16.4M a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 76% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.30 on revenue of $16.2M, against the analysts' −$0.21.
The last report
ADC Therapeutics SA reported revenue of $19.2M for the second quarter 2026 (+2% Y/Y), net loss $16.6M: Product revenues, net $18.6M, Royalties $614K. How it makes money → · Every quarter →
ADC Therapeutics SA's latest quarter
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
When does ADCT report earnings?
ADC Therapeutics SA is expected to report on Nov 9, 2026.
What are analysts expecting from ADC Therapeutics SA?
EPS of −$0.21 and revenue of $19.1M for the quarter.
Does ADC Therapeutics SA usually beat earnings?
It beat the consensus EPS estimate in 75% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.